Evidence map›Paper›PMID 40930551›Full record

Observational studyBMJ open2025

Are we closing the gender gap in academic oncology? An observational study of gender disparities in participant engagement at the ASCO 2024 annual meeting.

Hannah Christina Puhr, A Cammarota, M Ettaieb, Isabelle Flierman, T Gisinger, A Glas, Deniz C Guven, Alexander Siebenhüner, A Steindl, V Szydlik and 3 more

Abstract readObservational Study
In one paragraph

Observational study in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hannah Christina PuhrDepartment of Medicine I - Division of Oncology, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0002-7203-8732
A CammarotaHepatobiliary Immunopathology Lab, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy.
M EttaiebAmsterdam University Medical Centres, Amsterdam, Netherlands.
Isabelle FliermanAmsterdam University Medical Centres, Amsterdam, Netherlands.
T GisingerDepartment of Medicine III - Clinical Division of Endocrinology and Metabolism, Medical University of Vienna, Vienna, Austria.
A GlasUtrecht Medical Centre, Utrecht, Netherlands.
Deniz C GuvenDepartment of Medical Oncology, Hacettepe University, Ankara, Turkey.
Alexander SiebenhünerKlinik für Hämatologie und Onkologie, Hirslanden Zürich, Zürich, ZH, Switzerland.
A SteindlDepartment of Medicine I - Division of Oncology, Medical University of Vienna, Vienna, Austria.
V SzydlikFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
S ValpioneThe Christie NHS Foundation Trust, Manchester, England, UK.
M YipFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Hanneke W M van LaarhovenAmsterdam University Medical Centres, Amsterdam, Netherlands h.vanlaarhoven@amsterdamumc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveDespite global efforts, gender disparities in oncology may persist. Understanding these disparities within the context of major conferences can inform strategies to promote gender inclusiveness in the field. This study evaluates the participation of women and men at the American Society of Clinical Oncology (ASCO) 2024 congress, focusing on chairs, speakers and audience questioners.

designObservational study.

setting152 recorded sessions of the ASCO 2024 annual meeting, one of the largest conferences in the field of oncology, available on the ASCO website.

participantsIndividuals serving as chairs, speakers and audience members who asked questions. PRIMARY AND SECONDARY OUTCOME MEASURES: In this observational study, gender for chairs, speakers and audience questioners across 152 sessions of the ASCO 2024 congress was assessed by two independent reviewers using audio and video recordings. Speaking times for questions and responses were also evaluated. Statistical analyses, including χ

resultsWomen were well represented as chairs (n=124) and speakers (n=402) in 66% and 95% of sessions, respectively. However, only 21% of questions from the audience were posed by women, while 37% of questions were asked by men and 42% online or by chairs/speakers. Women were more likely to pose questions when the sessions were chaired by women (71% vs 53%; p=0.047). There were no statistically significant gender disparities concerning speaking time (questions: p=0.30; responses: 0.53). The response dynamics indicated a pattern of gender homogeneity, with individuals more frequently responding to questions from their own gender.

conclusionsWhile the balanced representation of women in leadership roles at the ASCO 2024 congress reflects positive development in gender equality, disparities in active participation persist. These findings underscore the need for strategies that not only promote women in visible roles but also foster an environment that supports their active engagement in scientific discussions.

Indexed as

Congresses as TopicGender EquityMedical OncologySexismSocieties, MedicalFemaleHumansMaleUnited StatesHealth EquityONCOLOGYSexual and Gender Minorities

Identifiers

PMID40930551
PMCPMC12421591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.